Insmed presents range of new study findings at american thoracic society 2023 international conference

—brensocatib reduced risk of exacerbations irrespective of disease severity in patients with non-cystic fibrosis bronchiectasis (ncfbe) in phase 2 willow subgroup analysis— —real-world cohort study shows fewer hospitalizations among patients with chronic obstructive pulmonary disease (copd) who received early diagnosis of nontuberculous mycobacterial (ntm) lung disease vs. patients in the late-diagnosis group— —analysis of willow data demonstrates reduction in azurocidin-1 (azu1) sputum levels with brensocatib treatment— bridgewater, n.j.
INSM Ratings Summary
INSM Quant Ranking